Gene modification therapies for hereditary diseases in the fetus
Prenatal Diagnosis · 2023-05 · 43 (5) · 674-686
DOI: 10.1002/pd.6347 ↗At a glance
Übersichtsarbeit in Prenatal Diagnosis, published online on 2023-04-05. Written by Citra N Z Mattar and 2 co-authors. Institution: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Major MEDLINE topics: Gene Transfer Techniques, Gene Editing. Cited 22 times so far (Crossref); 137 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Medical Research Council.
Abstract (original language)
Proof‐of‐principle disease models have demonstrated the feasibility of an intrauterine gene modification therapy (in utero gene therapy (IUGT)) approach to hereditary diseases as diverse as coagulation disorders, haemoglobinopathies, neurogenetic disorders, congenital metabolic, and pulmonary diseases. Gene addition, which requires the delivery of an integrating or episomal transgene to the target cell nucleus to be transcribed, and gene editing, where the mutation is corrected within the gene of origin, have both been used successfully to increase normal protein production in a bid to reverse or arrest pathology in utero. While most experimental models have employed lentiviral, adenoviral, and adeno‐associated viral vectors engineered to efficiently enter target cells, newer models have also demonstrated the applicability of non‐viral lipid nanoparticles. Amelioration of pathology is dependent primarily on achieving sustained therapeutic transgene expression, silencing of transgene expression, production of neutralising antibodies, the dilutional effect of the recipient's growth on the mass of transduced cells, and the degree of pre‐existing cellular damage. Safety assessment of any IUGT strategy will require long‐term postnatal surveillance of both the fetal recipient and the maternal bystander for cell and genome toxicity, oncogenic potential, immune‐responsiveness, and germline mutation. In this review, we discuss advances in the field and the push toward clinical translation of IUGT.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- National University Health Systems, Singapore, Singapore.
- KK Women's and Children's Hospital, Singapore, Singapore.
- Duke-NUS Medical School, Singapore, Singapore.
ORCID profiles: Citra N Z Mattar, Mahesh Choolani
Funding
- National Medical Research Council
Cite
APA
Mattar, C. N. Z., Chan, J. K. Y., & Choolani, M. (2023). Gene modification therapies for hereditary diseases in the fetus. Prenatal Diagnosis, 43(5), 674-686. https://doi.org/10.1002/pd.6347
Vancouver
Mattar CNZ, Chan JKY, Choolani M. Gene modification therapies for hereditary diseases in the fetus. Prenatal Diagnosis. 2023;43(5):674-686. doi:10.1002/pd.6347
BibTeX
@article{Mattar2023,
author = {Mattar, Citra N Z and Chan, Jerry K Y and Choolani, Mahesh},
title = {Gene modification therapies for hereditary diseases in the fetus},
journal = {Prenatal Diagnosis},
year = {2023},
volume = {43},
number = {5},
pages = {674--686},
doi = {10.1002/pd.6347}
}
EUVIMED